RT Book, Section
A1 Hill, Samuel L.
A1 Johnson, Peter W.M.
A2 Board, Ruth E.
A2 Nathan, Paul
A2 Newsom-Davis, Tom
A2 Papa, Sophie
A2 Johnson, Peter
SR Print(0)
ID 1160632587
T1 Immunotherapy: Past, Present and Future
T2 Problem Solving in Cancer Immunotherapy
YR 2019
FD 2019
PB EBN Health
PP New York, NY
SN 9780995595422
LK hemonc.mhmedical.com/content.aspx?aid=1160632587
RD 2021/01/27
AB The  intuitive  appeal  of  eliciting  an  effective  immune  response  against  cancers  has  long  been  recognized  but,  until  quite  recently,  rarely  fulfilled.  At  the  end  of  the  19th  century,  William  Coley,  a  New  York  sarcoma  surgeon,  noted  some  tumour  regressions  in  cancer  patients  infected  with  streptococci,  by  provoking  an  immune  response.1  But  such  responses  proved  hard  to  replicate  and  his  treatments  quickly  fell  out  of  favour.  The  idea,  however,  remained  potent.  Occasional  instances  of  spontaneous  tumour  regression2,3  or  prolonged  dormancy  suggested  some  form  of  ‘host  restraint’,  and  a  number  of  clinical  successes  kept  the  field  of  immunotherapy  alive,  despite  the  many  failed  attempts  at  treatment.